B lymphocyte-directed immunotherapy promotes long-term islet allograft survival in nonhuman primates.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 17965721.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We found that an induction immunotherapy regimen consisting of rabbit anti-thymocyte globulin (Thymoglobulin) and the monoclonal antibody to CD20 rituximab (Rituxan) promoted long-term islet allograft survival in cynomolgus macaques maintained on rapamycin monotherapy. B lymphocyte reconstitution after rituximab-mediated depletion was characterized by a preponderance of immature and transitional cells, whose persistence was associated with long-term islet allograft survival. Development of donor-specific alloantibodies was abrogated only in the setting of continued rapamycin monotherapy.
Medical subject headings
- Antibodies, Monoclonal
- B-Lymphocyte Subsets
- Graft Survival
- Immunotherapy, Active
- Islets of Langerhans Transplantation